Abstract
Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance
Highlights
15% of patients with ovarian cancer have a germline BRCA variation,[1] which has important implications, including increased sensitivity to platinum-based chemotherapy and poly(ADP-ribose) polymerase inhibitors and improved survival.[2]
Testing rates increased from 14.7% (55 of 375 patients) in 2008 to 46.4% (96 of 207 patients) in 2018; the median time to testing decreased from 280.0 to 72.5 days (Figure)
In adjusted analyses, testing was lower for older women and women with more comorbidities (Charlson Comorbidity Index score Ն2 vs 0: adjusted difference, −4.6 percentage points; 95% CI, −8.9 to −0.2 percentage points)
Summary
15% of patients with ovarian cancer have a germline BRCA (gBRCA) variation,[1] which has important implications, including increased sensitivity to platinum-based chemotherapy and poly(ADP-ribose) polymerase inhibitors and improved survival.[2]. Testing rates are reportedly between 10% and 30%,4 and few studies have examined commercially insured populations or identified patient-, physician-, and practice-level characteristics associated with testing rates
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
